|
市場調査レポート
商品コード
1471448
CD70標的療法の世界市場：市場機会と臨床試験に関する洞察（2024年）Global CD70 Targeting Therapies Market Opportunity & Clinical Trials Insight 2024 |
||||||
|
|
|||||||
| CD70標的療法の世界市場：市場機会と臨床試験に関する洞察（2024年） |
|
出版日: 2024年04月01日
発行: KuicK Research
ページ情報: 英文 120 Pages
納期: 即日から翌営業日
|
- 全表示
- 概要
- 図表
- 目次
がん治療におけるダイナミックな状況において、精密医療の登場は治療パラダイムを一変させ、個々の腫瘍のユニークなパターンを利用したオーダーメイドのアプローチを提供しています。近年、バイオテクノロジー企業や製薬企業の様々な利害関係者の好奇心が、腫瘍の発生と進行に関与する主要な分子 促進要因の同定によって強調された、ワンサイズ・フィット・オール・モデルからオーダーメイドの治療戦略へと脚光を浴びるようになっています。その中で、CD70タンパク質は有望な治療標的として浮上し、がん治療やその他の治療の領域で計り知れない可能性を秘めています。
治療標的としてのCD70の研究は、がん患者にとってより効果的で、個別化され、カスタマイズされた治療の選択肢のパノラマを広げています。当初、CD70タンパク質はT細胞やB細胞の活性化に関与していました。しかし、前臨床試験から得られた証拠は、CD70タンパク質がホスファチジルイノシトール-3キナーゼ（PI3K）とMAPキナーゼシグナル伝達経路の活性化を引き起こすことを示しています。このシグナル伝達経路の活性化は、さらに多数の転写因子の活性化をもたらし、それによって細胞の増殖と生存に関与する遺伝子の発現を引き起こし、がん疾患の原因となります。
前臨床試験による調査エビデンスの提供は、世界中の様々な利害関係者の信頼と探究心を高めるのに役立っています。そのため、数多くの製薬会社やバイオテクノロジー企業がCD70療法の開発を計画し、臨床試験を開始しました。CD70蛋白質療法市場を促進する重要な原動力の一つは、新規研究を実施するための共同研究の増加です。多くの企業が研究機関や病院と手を結び、CD70療法市場を前進させています。例えば、Chongqing Precision Biotechは、余剰のCD70前臨床・臨床研究を実施するために、中国のThe First Affiliated Hospital of Nanchang University、Zhejiang University、Shanxi Bethune Hospitalなどの研究機関や病院と提携しています。
現在、クサツズマブ（ARGX-110）は、白血病治療薬として臨床第II相段階に達した最も進んだCD70候補です。抗CD70抗体だけでなく、CAR-T細胞療法、CAR-NK療法、CD70タンパク質を標的とする4特異的抗体など、他の多くの治療アプローチもCD70治療の領域が年々進化していることを表しています。さらに、CD70タンパク質の研究がさらに進むにつれて、この領域は大きな展望と実りある未来を表しています。
当レポートは、世界のCD70標的療法市場について調査し、市場の概要とともに、薬剤動向、臨床試験動向、地域別動向、および市場に参入する企業の競合情勢などを提供しています。
目次
第1章 CD70標的療法の複雑さの解明
- CD70標的療法の概要
- CD70標的療法の経緯と開発
- CD70標的療法の前提条件
- 診断および予後バイオマーカーとしてのCD70の二重の役割
第2章 CD70標的療法の臨床アプローチ
- モノクローナル抗体
- 二重特異性抗体
- 四特異性抗体
- CAR T細胞療法
- 抗体薬物複合体
- CAR-NK療法
第3章 CD70標的療法の併用戦略
- 免疫療法との併用
- エピジェネティックモジュレーターとの併用
- 標的療法との併用
- 腫瘍溶解性ウイルス療法との併用
- 化学療法との併用
第4章 CD70標的療法：現在の臨床開発の動向とイノベーション、適応症別
- 白血病
- リンパ腫
- 婦人科がん
- 腎細胞がん
- 肺がん
- 自己免疫疾患と炎症性疾患
- ウイルス感染
第5章 世界のCD70標的療法の臨床試験の概要
- 相別
- 国別
- 企業別
- 適応症別
- 優先度別
- 患者セグメント
第6章 FDAおよびEMAの指定を受けたCD70標的療法候補
第7章 世界のCD70標的療法の現在の市場動向と開発
- 現在の市場概略
- 今後の市場予測
第8章 CD70標的療法市場の機会と臨床動向、地域別
- 米国
- 中国
- 欧州
第9章 企業とCD70標的療法開発プラットフォーム、技術別
第10章 世界のCD70標的療法市場力学
- 市場の促進要因
- 市場の課題
第11章 世界のCD70標的療法臨床試験の洞察
- 前臨床
- 第I相
- 第I/II相
- 第II相
第12章 競合情勢
- Acepodia
- Adaptimmune
- Adicet Bio
- Allogene Therapeutics
- Ambrx (Johnson & Johnson)
- Chinook Therapeutics (Novartis)
- CRISPR Therapeutics
- ImmuneOnco Biopharma
- Pfizer
- Poseida Therapeutics
List of Figures
1. Unlocking Intricacies for CD70 Targeting Therapy
- 1.1 Overview to CD70 Targeting Therapy
- 1.2 Chronicle & Development of CD70 Targeting Therapy
- 1.3 The Prerequisite for CD70 Targeting Therapy
- 1.4 Dual Role of CD70 As Diagnostic & Prognostic Biomarker
2. Clinical Approaches For CD70 Targeting Therapy
- 2.1 Monoclonal Antibody
- 2.2 Bispecific Antibody
- 2.3 Tetraspecific Antibody
- 2.4 CAR T Cell Therapy
- 2.5 Antibody Drug Conjugate
- 2.6 CAR-NK Therapy
3. Combination Stratagems for CD70 Targeting Therapies
- 3.1 In Combination with Immunotherapy
- 3.2 In Combination with Epigenetic Modulators
- 3.3 In Combination with Targeted Therapy
- 3.4 In Combination with Oncolytic Virus Therapy
- 3.5 In Combination with Chemotherapy
4. CD70 Targeting Therapy By Indications: Current Clinical Development Trends & Innovations
- 4.1 Leukemia
- 4.2 Lymphoma
- 4.3 Gynecologic Cancer
- 4.4 Renal Cell Carcinoma
- 4.5 Lung Cancer
- 4.6 Autoimmune & Inflammatory Disease
- 4.7 Viral Infections
5. Global CD 70 Targeting Therapy Clinical Trials Overview
- 5.1 By Phase
- 5.2 By Country
- 5.3 By Company
- 5.4 By Indication
- 5.5 By Priority Status
- 5.6 Patient Segment
6. CD70 Targeting Therapy Candidates Granted FDA & EMA Designations
7. Global CD70 Targeting Therapy Current Market Trend & Developments
- 7.1 Current Market Outline
- 7.2 Future Market Forecast
8. CD70 Targeting Market Opportunity & Clinical Trends by Region
- 8.1 US
- 8.2 China
- 8.3 Europe
9. CD70 Targeting Therapy Development Platforms By Company & Technology
- 9.1 AlloCAR T Platform
- 9.2 Gamma Delta Cell Platform
- 9.3 Tailwind Platform
- 9.4 DARPin Platform
- 9.5 SIMPLE antibody platform
- 9.6 Potelligent Technology
10. Global CD70 Targeting Therapy Market Dynamics
- 10.1 Market Drivers
- 10.2 Market Challenges
11. Global CD 70 Targeting Therapies Clinical Trials Insight
- 11.1 Preclinical
- 11.2 Phase I
- 11.3 Phase I/II
- 11.4 Phase II
12. Competitive Landscape
- 12.1 Acepodia
- 12.2 Adaptimmune (TCR2 Therapeutics )
- 12.3 Adicet Bio
- 12.4 Allogene Therapeutics
- 12.5 Ambrx (Johnson & Johnson)
- 12.6 Chinook Therapeutics (Novartis)
- 12.7 CRISPR Therapeutics
- 12.8 ImmuneOnco Biopharma
- 12.9 Pfizer
- 12.10 Poseida Therapeutics
Global CD70 Targeting Therapies Market Opportunity & Clinical Trials Insight 2024 Report Highlights:
- CD70 Targeting Therapies In Clinical Trials: > 20 Therapies
- CD 70 Targeting Therapies Clinical Trials Insight By Company, Country, Indication & Phase
- Insight On CD70 Targeting Therapy Technology Platforms: 6 Platforms
- FDA & EMA Designations Insight: Orphan, FTD, RMAT Designation
- Combination Stratagems for CD70 Targeting Therapies
- Insight On 10 Companies Involved In Development Of CD70 Therapies
In the dynamic landscape of cancer therapeutics, the emergence of precision medicine has transformed treatment paradigms, offering tailored approaches that take advantage of the unique patterns of individual tumors. Recently, the curiosity of various stakeholders from the biotech and pharma companies have turned the limelight from a one size fits all model to a tailored therapeutic strategy that has been underscored by the identification of key molecular drivers implicated in tumorigenesis and progression. Among these, CD70 protein has emerged as a promising therapeutic target, clenching immense potential in the realm of cancer therapy and other treatments.
The research of CD70 as a therapeutic target clenches the panorama of more effective, personalized and customized therapy choices for cancer patients. Initially, the CD70 protein was involved in T cell and B cell activation. However, augmenting evidences from preclinical studies signifies that CD70 protein causes activation of the phosphatidylinositol-3 kinase (PI3K) together with MAP kinase signaling pathways. This activation of signaling pathways further results in activation of numerous transcription factors and thereby the expression of genes involved in cell growth along with survival and causing cancer diseases.
Bestowing research evidences from preclinical studies aid to build confidence and inquisitiveness among various stakeholders across the globe. Therefore, numerous pharma and biotech companies planned to develop CD70 therapy and initiated clinical trials. One of the significant prime movers that aid to advance CD70 protein therapy market is the rise in research collaborations to conduct novel studies. Many firms are joining hands with research institute and hospitals to headway CD70 therapy market. For instance, Chongqing Precision Biotech has partnership with institutes and hospitals, including The First Affiliated Hospital of Nanchang University, Zhejiang University or Shanxi Bethune Hospital etc., in China to conduct surplus CD70 preclinical and clinical studies.
Concurrently, in the pharmaceutical sector, CD70 targeted therapeutic intervention characterize a promising revolution area. Over the preceding decennium, the sphere of global CD70 therapy market has witnessed the development of several novel, innovative as well as advanced contenders targeting CD70. For instance, candidates like SGN-CD70, bi-4SCAR GD2/ CD70 T cells, CD70 CAR-T cells, CB dualCAR- NK19/70, CTX130, CTX131, ALLO-316 and others have been developed by in the preceding years for the treatment of cancer ailments. As research and advancement expands, it is anticipated that numerous other innovative CD70 therapy will be perceived in future.
Moreover, in order to further augment the therapeutic window in conjugation with boost efficacy, pharma companies have initiated the combinational study of CD70 therapy with other therapies. Currently, a handful of combinations of CD70 therapy are being invested with immunotherapies like CAR-T therapy combination or amalgamation of CAR-T with monoclonal antibody, targeted therapies, chemotherapy, epigenetic modulators, oncolytic viruses and others. The combinational study for CD70 therapy represents a novel as well as compelling frontier in the commercial CD70 therapy landscape.
Solitary of the key characteristics which aid to amplify the sphere of CD70 targeted therapy is fostering investments and collaborations. These partnerships and investments among academic institutions, smaller biotech firms, and larger pharmaceutical companies also aid to speed up the discovery and commercialization of CD70 therapy. For instance, in February 2024, ProfoundBio has raised an investment of US$ 112 Million in Series B financing round in order to advance in its preclinical programs, including PRO1160, a CD70 targeted antibody drug conjugate.
All these examples demonstrate that the realm of CD70 therapy is burgeoning at an incredible gait. At present, US dominates the CD70 therapy segment in terms of research and development. However, China is additionally up surging and expanding the CD70 therapy arena by developing innovative CD70 candidates coupled with initiating many clinical trials. The evolutions from one size fits all model to a tailored therapeutic strategy suggests that developing CD70 therapy clenches immense potential.
Currently, Cusatuzumab (ARGX-110) is the most advanced CD70 candidates that have reached phase II clinical stage for leukemia treatment. In addition to anti-CD70 antibodies, multitudinous other therapeutic approach like CAR-T cell therapy, CAR-NK therapy or tetraspecific antibodies targeting CD70 protein represents that the domain of CD70 therapy is evolving year by year. Moreover, as research further increases for CD70 protein, the domain represents a huge prospect and a fruitful future.
Table of Contents
1. Unlocking Intricacies for CD70 Targeting Therapy
- 1.1 Overview to CD70 Targeting Therapy
- 1.2 Chronicle & Development of CD70 Targeting Therapy
- 1.3 The Prerequisite for CD70 Targeting Therapy
- 1.4 Dual Role of CD70 As Diagnostic & Prognostic Biomarker
2. Clinical Approaches For CD70 Targeting Therapy
- 2.1 Monoclonal Antibody
- 2.2 Bispecific Antibody
- 2.3 Tetraspecific Antibody
- 2.4 CAR T Cell Therapy
- 2.5 Antibody Drug Conjugate
- 2.6 CAR-NK Therapy
3. Combination Stratagems for CD70 Targeting Therapies
- 3.1 In Combination with Immunotherapy
- 3.2 In Combination with Epigenetic Modulators
- 3.3 In Combination with Targeted Therapy
- 3.4 In Combination with Oncolytic Virus Therapy
- 3.5 In Combination with Chemotherapy
4. CD70 Targeting Therapy By Indications: Current Clinical Development Trends & Innovations
- 4.1 Leukemia
- 4.2 Lymphoma
- 4.3 Gynecologic Cancer
- 4.4 Renal Cell Carcinoma
- 4.5 Lung Cancer
- 4.6 Autoimmune & Inflammatory Disease
- 4.7 Viral Infections
5. Global CD 70 Targeting Therapy Clinical Trials Overview
- 5.1 By Phase
- 5.2 By Country
- 5.3 By Company
- 5.4 By Indication
- 5.5 By Priority Status
- 5.6 Patient Segment
6. CD70 Targeting Therapy Candidates Granted FDA & EMA Designations
7. Global CD70 Targeting Therapy Current Market Trend & Developments
- 7.1 Current Market Outline
- 7.2 Future Market Forecast
8. CD70 Targeting Market Opportunity & Clinical Trends by Region
- 8.1 US
- 8.2 China
- 8.3 Europe
9. CD70 Targeting Therapy Development Platforms By Company & Technology
- 9.1 AlloCAR T Platform
- 9.2 Gamma Delta Cell Platform
- 9.3 Tailwind Platform
- 9.4 DARPin Platform
- 9.5 SIMPLE antibody platform
- 9.6 Potelligent Technology
10. Global CD70 Targeting Therapy Market Dynamics
- 10.1 Market Drivers
- 10.2 Market Challenges
11. Global CD 70 Targeting Therapies Clinical Trials Insight
- 11.1 Preclinical
- 11.2 Phase I
- 11.3 Phase I/II
- 11.4 Phase II
12. Competitive Landscape
- 12.1 Acepodia
- 12.2 Adaptimmune (TCR2 Therapeutics )
- 12.3 Adicet Bio
- 12.4 Allogene Therapeutics
- 12.5 Ambrx (Johnson & Johnson)
- 12.6 Chinook Therapeutics (Novartis)
- 12.7 CRISPR Therapeutics
- 12.8 ImmuneOnco Biopharma
- 12.9 Pfizer
- 12.10 Poseida Therapeutics
